🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

850 results for “Elan” Clear

  1. Pembrolizumab

    Syndax Pharmaceuticals

    Metastatic Uveal Melanoma

    phase 2 small molecule completed

    1 trial

  2. Pembrolizumab

    Merck KGaA, Darmstadt, Germany

    Melanoma

    phase 2 mab completed

    1 trial

  3. Peptide A49 associated to melanin, Peptide A52 associated to melanin, Litenimod solution

    Pari Pharma GmbH

    glioblastoma

    phase 2 small molecule active

    1 trial

  4. Phase 1b: APG-115+pembrolizumab

    Ascentage Pharma Group

    Unresectable or Metastatic Melanoma or Advanced Solid Tumors

    phase 2 small molecule active

    1 trial

  5. Placebo

    Jazz Pharmaceuticals Ireland Limited

    Viruria

    phase 2 small molecule completed

    1 trial

  6. Placebo

    Theravance Biopharma Ireland Umited

    Crohn's Disease

    phase 2 small molecule terminated

    1 trial

  7. Placebo

    Theravance Biopharma Ireland Umited

    Chronic Obstructive Pulmonary Disease, COPD

    phase 2 small molecule completed

    1 trial

  8. Placebo

    Jazz Pharmaceuticals Ireland Limited

    Parkinson Disease

    phase 2 small molecule completed

    1 trial

  9. Placebo

    Jazz Pharmaceuticals Ireland Limited

    Schizophrenia

    phase 2 small molecule completed

    1 trial

  10. Placebo to V940, KEYTRUDA 25 mg/mL concentrate for solution for infusion, mRNA-4157

    Merck Sharp and Dohme

    Melanoma

    phase 2 small molecule active

    1 trial

  11. Placebo to match ALKS 2680, ALKS 2680, ALKS 2680, ALKS 2680

    Alkermes Pharma Ireland

    Narcolepsy Type 1

    phase 2 small molecule active

    1 trial

  12. Placebo to match ALKS 2680, ALKS 2680, ALKS 2680, ALKS 2680

    Alkermes Pharma Ireland

    Narcolepsy Type 2

    phase 2 small molecule active

    1 trial

  13. Placebo, BFB759

    Blue Earth Diagnostics Ireland Ltd

    Hidradenitis Suppurativa

    phase 2 small molecule active

    1 trial

  14. Placebo: Normal Saline - Solution for injection, Daxdilimab

    Elan Pharma International

    Primary Discoid Lupus Erythematosus

    phase 2 small molecule active

    1 trial

  15. Presatovir

    Gilead Sciences Ireland UC

    Respiratory Syncytial Virus

    phase 2 small molecule completed

    1 trial

  16. REGN10597

    Regeneron UK Limited

    Melanoma

    phase 2 small molecule active

    1 trial

  17. REOLYSIN

    ONCOLYTICS BIOTECH INC

    Metastatic Melanoma

    phase 2 mab completed

    1 trial

  18. RO7247669

    Hoffmann-La Roche

    Melanoma

    phase 2 small molecule completed

    1 trial

  19. RO7247669

    Hoffmann-La Roche

    Unresectable or Metastatic Melanoma

    phase 2 small molecule active

    1 trial

  20. Revefenacin Inhalation Solution [Yupelri]

    Theravance Biopharma Ireland Umited

    COPD

    phase 2 small molecule completed

    1 trial

  21. SKY0402

    Pacira Ireland Limited

    Inguinal Hernia

    phase 2 small molecule completed

    1 trial

  22. SKY0402

    Pacira Ireland Limited

    Postoperative Pain

    phase 2 small molecule completed

    3 trials

  23. SKY0402 + bupivacaine HCl

    Pacira Ireland Limited

    Postoperative Pain

    phase 2 small molecule completed

    1 trial

  24. SOF

    Gilead Sciences Ireland UC

    Hepatitis C Virus Infection

    phase 2 small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources